TERT启动子突变与MGMT启动子甲基化介导的IDH野生型胶质母细胞瘤对替莫唑胺敏感性:是否存在关联?
该研究在德国胶质瘤网络前瞻性队列(n=298)和杜塞尔多夫/苏黎世回顾性队列(n=302)的IDH野生型胶质母细胞瘤患者中,回顾性评估MGMT启动子甲基化与TERT启动子突变状态。结果显示两个队列均未证实TERT启动子突变在MGMT启动子甲基化肿瘤中带来额外获益,提示TERT启动子突变检测可能不需要用于预测IDH野生型胶质母细胞瘤的替莫唑胺敏感性。
要点
- 两个独立队列均未证实TERT启动子突变在MGMT启动子甲基化IDH野生型胶质母细胞瘤中增强替莫唑胺获益。
- 仅在GGN队列中,TERT启动子突变与MGMT启动子未甲基化患者较差结局中度相关(HR 1.74;95%CI 1.07-2.82;p=0.026)。
- TERT启动子突变检测可能不需要用于预测IDH野生型胶质母细胞瘤的替莫唑胺敏感性。
核心结论
- 分析两个独立胶质母细胞瘤患者队列未证实既往数据,即TERT启动子突变在MGMT启动子甲基化胶质母细胞瘤中赋予替莫唑胺增强获益。
- 因此,TERT启动子突变检测可能不需要用于预测IDH野生型胶质母细胞瘤患者的替莫唑胺敏感性。
研究设计与样本
- 回顾性评估德国胶质瘤网络(GGN)前瞻性队列中IDH野生型胶质母细胞瘤患者(n=298)的MGMT启动子甲基化和TERT启动子突变状态。
- 回顾性评估来自德国杜塞尔多夫和瑞士苏黎世的独立回顾性队列(n=302)的MGMT启动子甲基化和TERT启动子突变状态。
主要发现
- 在GGN队列中,TERT启动子突变与MGMT启动子未甲基化肿瘤患者较差结局中度相关(风险比1.74;95%置信区间:1.07-2.82;p=0.026),但杜塞尔多夫/苏黎世队列中未观察到该关联。
- 在两个队列中,TERT启动子突变与MGMT启动子甲基化肿瘤患者更好结局均无关。
- 两种不同的TERT启动子热点突变(C228T和C250T)与不同结局无关。
临床怎么用
- 对于IDH野生型胶质母细胞瘤,预测替莫唑胺敏感性可能仍以MGMT启动子甲基化状态为主要依据。
- 不建议常规检测TERT启动子突变来预测IDH野生型胶质母细胞瘤患者对替莫唑胺的敏感性。
局限性
- 研究为回顾性评估MGMT启动子甲基化和TERT启动子突变状态,尽管GGN队列为前瞻性队列。
- 两个队列中TERT启动子突变与结局的关联结果不一致,仅GGN队列中观察到与MGMT启动子未甲基化患者较差结局的中度关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM OF THE STUDY: Benefit from temozolomide (TMZ) chemotherapy in the treatment of isocitrate dehydrogenase (IDH)-wild-type glioblastoma is essentially limited to patients with O6-methylguanine DNA methyltransferase (MGMT) promoter-methylated tumours. Recent studies suggested that telomerase reverse transcriptase (TERT) promoter hotspot mutations may have an impact on the prognostic role of the MGMT status in patients with glioblastoma. METHODS: MGMT promoter methylation and TERT promoter mutation status were retrospectively assessed in a prospective cohort of patients with IDH-wild-type glioblastoma of the German Glioma Network (GGN) (n = 298) and an independent retrospective cohort from Düsseldorf, Germany, and Zurich, Switzerland (n = 302). RESULTS: In the GGN cohort, but not in the Düsseldorf/Zurich cohort, TERT promoter mutation was moderately associated with inferior outcomes in patients with MGMT promoter-unmethylated tumours (hazard ratio 1.74; 95% confidence interval: 1.07-2.82; p = 0.026). TERT promoter mutations were not associated with better outcomes in patients with MGMT promoter-methylated tumours in either cohort. The two different TERT promoter hotspot mutations (C228T and C250T) were not linked to distinct outcomes. CONCLUSIONS: Analysis of two independent cohorts of patients with glioblastoma did not confirm previous data, suggesting that TERT promoter mutations confer an enhanced benefit from TMZ in patients with MGMT promoter-methylated glioblastoma. Thus, diagnostic testing for TERT promoter mutations may not be required for prediction of TMZ sensitivity in patients with IDH-wild-type glioblastoma.
引用
- Gramatzki D, Felsberg J, Hentschel B, et al. Telomerase reverse transcriptase promoter mutation- and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link? Eur J Cancer. 2021. PMID: 33631540. doi:10.1016/j.ejca.2021.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。